NYSEAMERICAN:DXR Daxor (DXR) Stock Price, News & Analysis → FW: 234x Gain (From Weiss Ratings) (Ad) Free DXR Stock Alerts $9.80 -0.08 (-0.81%) (As of 05:22 PM ET) Add Compare Share Share Today's Range$9.51▼$9.9550-Day Range N/A52-Week Range$7.11▼$13.13Volume5,056 shsAverage Volume3,475 shsMarket Capitalization$46.45 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsStock AnalysisChartFinancialsHeadlinesSEC Filings Get Daxor alerts: Email Address Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About Daxor Stock (NYSEAMERICAN:DXR)Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.Read More DXR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DXR Stock News HeadlinesApril 16, 2024 | finance.yahoo.comNew Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of CongestionApril 15, 2024 | finance.yahoo.comDAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)May 3, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 1, 2024 | finance.yahoo.comDaxor Corporation to Exhibit at the American College of Cardiology for ACC.24March 29, 2024 | investing.comDaxor CFO Michel Robert J buys $6.5k in company stockMarch 28, 2024 | money.usnews.comDestiny Tech100 IncMarch 28, 2024 | finance.yahoo.comDaxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Call TranscriptMarch 23, 2024 | wsj.comDaxor Corp.May 3, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 22, 2024 | finance.yahoo.comDaxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024March 8, 2024 | finance.yahoo.comMulti-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure PatientsFebruary 12, 2024 | finance.yahoo.comDaxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer AcquisitionsFebruary 9, 2024 | benzinga.comDaxor Stock (NASDAQ:DXR) Insider TradesFebruary 7, 2024 | finance.yahoo.comDaxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing AccountsJanuary 29, 2024 | finance.yahoo.comDaxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual MeetingJanuary 16, 2024 | finance.yahoo.comDaxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care CongressJanuary 9, 2024 | finance.yahoo.comDAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMESJanuary 3, 2024 | msn.comDaxor seeks US FDA approval for blood volume analyserJanuary 2, 2024 | finance.yahoo.comDaxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume AnalyzerNovember 13, 2023 | seekingalpha.comAspira Women’s Health GAAP EPS of -$0.48 beats by $0.03, revenue of $2.22M misses by $0.68MNovember 13, 2023 | finanznachrichten.deDaxor Corporation: New Randomized Controlled Trial Demonstrates the Efficacy of Daxor's BVA Guided-Care in Heart Failure PatientsNovember 13, 2023 | finance.yahoo.comNew Randomized Controlled Trial Demonstrates the Efficacy of Daxor’s BVA Guided-Care in Heart Failure PatientsNovember 9, 2023 | finance.yahoo.comDaxor Corporation Awarded New Patent for Remote Monitoring of Blood VolumeNovember 7, 2023 | msn.comNeuronetics GAAP EPS of -$0.33 misses by $0.02, revenue of $17.9M beats by $0.32MNovember 5, 2023 | benzinga.comChief Financial Officer at Daxor Acquires Company Stock Options Worth 5,000 SharesOctober 13, 2023 | finance.yahoo.comExpert Panelists Advocate Use of Daxor’s Technology to Optimize Treatment at Heart Failure Society of America Annual Scientific MeetingOctober 11, 2023 | finance.yahoo.comNew Data from Banner University Medicine Demonstrating Effectiveness of BVA-100® Use in Ambulatory Heart Failure Patients Presented at Heart Failure Society of America Annual Scientific MeetingSee More Headlines Receive DXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Daxor and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Medical Instruments & Supplies Sub-IndustryN/A Current SymbolNYSEAMERICAN:DXR Previous SymbolNYSE:DXR CUSIPN/A CIK27367 Webwww.daxor.com Phone(865) 425-0555Fax212-244-0806EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares4,740,000Free Float1,866,000Market Cap$46.83 million OptionableNot Optionable Beta-0.50 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Michael Richard Feldschuh (Age 55)Chairman, President & CEO Comp: $100kMr. Jonathan Adam Feldschuh (Age 59)Chief Scientific Officer & Director Comp: $127.92kMr. Robert J. Michel CPA (Age 67)CPA, M.B.A., CFO, Chief Compliance Officer & Corporate Secretary Ms. Linda CooperVice President of Development & OperationsMs. Kathryn A. KornafelSenior VP of Marketing & Commercial DevelopmentMr. Guido ManzoVice President of SalesMs. Jean OertelSenior Vice President Commercialization & Customer ExperienceMore ExecutivesKey CompetitorsNanoString TechnologiesNASDAQ:NSTGQJupiter WellnessNASDAQ:JUPWPrenetics GlobalNASDAQ:PREQuince TherapeuticsNASDAQ:QNCXNabriva TherapeuticsNASDAQ:NBRVView All Competitors DXR Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Daxor own? Based on aggregate information from My MarketBeat watchlists, some companies that other Daxor investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Pfizer (PFE), ContraFect (CFRX), Dynavax Technologies (DVAX), iBio (IBIO), Micron Technology (MU) and How do I buy shares of Daxor? Shares of DXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:DXR) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Gold Grab of the CenturyColonial MetalsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsREAD THIS – If You Missed Out On The AI BoomBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
